Sign In
Last checked at 
16 Dec 2019 07:00
16 December 2019
Scancell Holdings plc
("Scancell" or the "Company")
Second agreement for AvidiMab™ monoclonal antibody platform signed with Chinese biotech company
Scancell, the developer of novel immunotherapies for the treatment of cancer, is pleased to announce that it has signed a second collaboration and non-exclusive research agreement with a Chinese biotechnology company to assess monoclonal antibodies (mAbs) targeting tumour-associated glycans (TaGs) that have been enhanced with its proprietary AvidiMab™ technology.
Today's announcement follows the first collaboration agreement for AvidiMab™ and the pipeline of TaG mAbs with a leading antibody technology company which was announced in September 2019.
Under the terms of the collaboration and research agreement, this new collaboration partner will conduct preclinical studies to evaluate Scancell's anti-TaG mAbs, including those enhanced with AvidiMab™, for the treatment of cancer.
Dr Cliff Holloway, Chief Executive Officer, Scancell, commented:
"We are pleased to announce this second collaboration agreement for the AvidiMab™ platform. As previously stated, we believe our novel AvidiMab™ platform and tumour associated glycan antibodies have broad partnering potential and this has been further demonstrated by today's agreement, the second in four months. This is our first collaboration in China, and we look forward to updating the market on further progress with this platform in due course."
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR).
For Further Information:
Scancell Holdings plc | ||
Dr John Chiplin, Chairman | +44 (0) 20 3727 1000 | |
Dr Cliff Holloway, CEO | ||
Panmure Gordon (UK) Limited (Nominated Adviser and Corporate broker) | ||
Freddy Crossley/Emma Earl | +44 (0) 20 7886 2500 | |
FTI Consulting Simon Conway/Natalie Garland-Collins | +44 (0) 20 3727 1000 |
About Scancell
Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms.
ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system. They have the potential to be used as monotherapy or in combination with checkpoint inhibitors and other agents. This platform has the potential to enhance tumour destruction, prevent disease recurrence and extend survival.
·; SCIB1, the lead programme, is being developed for the treatment of melanoma. A phase 1/2 clinical trial has so far successfully demonstrated survival data of more than five years.
·; SCIB2 is being developed for the treatment of non-small cell lung cancer and other solid tumours. Scancell has entered into a clinical development partnership with Cancer Research UK (CRUK) for SCIB2.
Moditope® represents a completely new class of potent and selective immunotherapy agents based on stress-induced post-translational modifications (siPTM). It stimulates the production of killer CD4 T cells which overcome the immune suppression induced by tumours, allowing activated T cells to seek out and kill tumour cells that would otherwise be hidden from the immune system. Moditope® alone, or in combination with other agents, has the potential to treat a wide variety of cancers.
·; Modi-1 is being developed for the treatment of solid tumours including triple negative breast cancer, ovarian cancer and head and neck cancer.
AvidiMab™ is a patent protected technology platform which increases the avidity of human antibodies by promoting non-covalent Fc-Fc interactions. This modification induces the direct tumour cell killing properties of Scancell's anti-glycan monoclonal antibodies (mAbs) but has broad potential to increase the avidity or potency of any therapeutic monoclonal antibody including those being developed for autoimmune diseases, as well as cancer.
For further details, please see our website: www.scancell.co.uk
Follow the stocks
